Tvardi Therapeutics Hits New 52-Week High at $40.77

Tvardi Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 40.77 on September 18, 2025. This achievement marks a notable increase from its 52-week low of USD 8.13, reflecting a substantial upward trend in the stock's performance over the past year.
The company's market capitalization stands at USD 278 million, positioning it within the microcap category. Despite the impressive stock price movement, Tvardi Therapeutics has not declared any dividends, maintaining a dividend yield of 0.00%. The company’s financial metrics indicate a debt-to-equity ratio of -1.24, which suggests a unique capital structure, while the price-to-book ratio is reported at 8.45.

In comparison to the S&P 500, Tvardi Therapeutics has demonstrated a performance of 17.14% over the past year, highlighting its relative strength in the market. As the company continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry, this new high underscores its current market position and performance trajectory.